Half Year Results 

Hikma delivers for the faithful

Hikma delivers for the faithful

In the last six months, Hikma’s (HIK) new management has provided a masterclass in restoring faith. A cautiously optimistic outlook statement, five separate drug launches and two strategic partnership announcements have sent the group’s share price up 89 per cent since the full-year results. Fortunately, half-year numbers have more than justified that rise: operating profit was up 23 per cent on a like-for-like basis off the back of solid revenue growth and widening margins. The question now is whether Hikma can keep going?

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now